Trials / Completed
CompletedNCT04146324
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
A Prospective Observational Study in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma in Australia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to estimate the effectiveness of nivolumab when given to participants after removing their cancer with surgery, over a 5-year follow-up, in real-world conditions in Australia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nivolumab | Administered as adjuvant therapy as per the market authorization in Australia |
Timeline
- Start date
- 2019-12-12
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
- First posted
- 2019-10-31
- Last updated
- 2025-01-24
Locations
9 sites across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04146324. Inclusion in this directory is not an endorsement.